Britain's lawmakers vote to legalize assisted dying, a landmark move after a fraught national debate
Lawmakers in Britain have narrowly approved a bill to legalize assisted dying for terminally ill people, capping a fraught debate in Parliament and across the country that cut across political, religious and legal divides.
MPs passed the bill by 314 votes to 291, in their final say on the question. The bill – which has split lawmakers and sparked impassioned conversations with their constituents the breadth of Britain – will now move to the House of Lords for its final rounds of scrutiny.
Friday's vote puts Britain firmly on track to join a small club of nations that have legalized the process, and one of the largest by population to allow it.
It allows people with a terminal condition and less than six months to live to take a substance to end their lives, as long as they are capable of making the decision themselves. Two doctors and a panel would need to sign off on the choice.
Canada, New Zealand, Spain and most of Australia allow assisted dying in some form, as do several US states, including Oregon, Washington and California.
Friday's vote in Parliament coincided with a charged public debate about whether the state should be dictating the choices available to Britons in the final moments of their lives.
Proponents included Esther Rantzen, a BBC TV presenter with advanced lung cancer, who argued that the choice would save millions from unnecessary suffering.
'If we don't vote to change the law today, what does that mean?,' asked Kim Leadbeater, the MP who introduced the bill last year. 'It means we will have many more years of heartbreaking stories from terminally ill people and their families, of pain and trauma, suicide attempts, PTSD, lonely trips to (clinics in) Switzerland, police investigations.'
The option, she said, is 'not a choice between living and dying: it is a choice for terminally ill people about how they die.'
But opponents have criticized the bill on religious and ethical grounds, and raised issues with a legislative process they accuse of being opaque.
Former British Prime Minister Gordon Brown argued that fixing Britain's strained end-of-live care system should be prioritized, writing in a rare intervention in The Guardian that the bill 'would privilege the legal right to assisted dying without guaranteeing anything approaching an equivalent right to high-quality palliative care for those close to death.'
Seriously ill people 'need the health and social care system fixing first,' Labour MP Vicky Foxcroft said in Parliament Friday. 'They want us as parliamentarians to assist them to live, not to die.'
Friday's debate was concluded with a free vote, meaning that MPs were allowed to decide for or against the bill according to their conscience, and free from any party-line whipping.
The proposed bill is broadly in line with the Oregon model, and does not go as far as Switzerland, the Netherlands and Canada, which allow assisted death in cases of suffering, not just for terminally ill people. It differs from euthanasia, the process in which another person deliberately ends someone's life to relieve suffering.
It is currently a crime to help somebody die in England and Wales, punishable by up to 14 years in prison. Performing euthanasia on a person, meanwhile, is considered murder or manslaughter.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Rantzen: MPs backing assisted dying Bill will protect people from ‘bad death'
Dame Esther Rantzen has said MPs backing the assisted dying Bill will make a 'huge positive difference' and protect terminally ill people from a 'bad death'. The Terminally Ill Adults (End of Life) Bill will now head to the Lords after clearing the Commons on Friday afternoon, with MPs voting 314 in favour, 291 against, majority 23. Dame Esther, a notable supporter of campaign Dignity in Dying who has stage four lung cancer, told the PA news agency: 'This will make a huge positive difference, protecting millions of terminally ill patients and their families from the agony and loss of dignity created by a bad death. 'Thank you, Parliament.' Campaigners inside Parliament and outside in Parliament Square were jubilant and tearful following the result of the vote. Some MPs lined up to shake hands with or hug Kim Leadbeater, the Bill's sponsor through the Commons. Ms Leadbeater described the vote as a 'result that so many people need'. The Labour MP for Spen Valley said: 'Thank goodness we got the result that so many people need, but I also feel that it was done really respectfully and the atmosphere in the chamber was very civilised.' Outside, a cheer erupted as the result was announced on a livestream to a crowd who had huddled together in anticipation. Many cried and hugged each other, while others popped champagne. Dame Esther's daughter, Rebecca Wilcox, called her mother in front of supporters and told her she wished she was here. Ms Wilcox came to Parliament Square following the vote and hugged fellow campaigners and friends. She told PA that she gave Ms Leadbeater's mum a 'big hug' following the result and added: 'I don't know whether to have a drink or a really big cry. 'There were a few of us in the public gallery and we were all holding hands. I felt like we were on a rollercoaster. 'It was the longest pause when everyone came in and we were waiting for the four and when I heard a three for the 'ayes' I was quite positive. 'It was quite extraordinary. I turned around and gave Kim's mum a great big hug.' Sarah Wootton, chief executive of Dignity in Dying, told the crowd: 'This is for all the people who couldn't be here today. This vote sends a clear message. Parliament stands with the public and change is coming.' Sian Berry, a Green Party MP and one of the proposers of the Bill, told PA: 'We all have experience of loved ones at the end of their lives that have influenced this. So many of my constituents have written to me telling me their stories. You really feel the importance of what you're doing this for. 'I'm confident we have made the Bill robust and I do believe this reflects public opinion.' Supporter Tim Murphy, 39, from London, said: 'My friend David went to Dignitas four years ago and he had to die sooner than he should have had there been a workable law in this country. 'This will impact so many people. So much of the [opposition] campaign has been hypothetical situations in the future but not taking into consideration the actual deaths that have occurred.' Those opposed to the Bill were visibly disappointed. People had gathered to pray before the vote but the crowd of white-shirted campaigners quickly dispersed following the result. Many packed up their signs and left the square and did not speak to the press. Bishop of London Dame Sarah Mullally, a former chief nursing officer for England who sits in the House of Lords, said: 'Every person is of immeasurable and irreducible value, and should be able to access the care and support that they need – a principle that I know is shared by those of all faiths and none. 'We must oppose a law that puts the vulnerable at risk and instead work to improve funding and access to desperately needed palliative care services.' Sean Redfearn, 26, representing Christian Concern, said: 'It's disappointing the nation is stepping closer for people to take their own lives.' 'There is no progress as progress suggests flourishing and there's no flourishing with allowing the ending of a life.'
Wall Street Journal
36 minutes ago
- Wall Street Journal
Week Ahead for FX, Bonds: PMI Data, Middle East Conflict in Focus
Preliminary purchasing managers' surveys in the eurozone, U.K. and U.S. are among the biggest highlights in the week ahead. The surveys on manufacturing and services activity are an important indicator of economic growth. The data come amid concerns about President Trump's tariff policy and the Israel-Iran conflict. Noting that the global PMI data for May signaled some improvements in current and expected future output growth, S&P economists said in a note: 'With tensions rising in the Middle East, pushing oil prices sharply higher, the flash PMI data will be keenly assessed to see whether April really represented 'peak gloom' in terms of business confidence, or whether executives consider the economic and political environment to have deteriorated further.'
Medscape
36 minutes ago
- Medscape
Darzalex Monotherapy OK'd for Smoldering Multiple Myeloma
At its June 2025 meeting, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended extending the indications for Darzalex (daratumumab) solution for injection as monotherapy to the treatment of adult patients with smoldering multiple myeloma at high risk of developing multiple myeloma. Darzalex is a monoclonal antibody used to treat adults with multiple myeloma and light chain amyloidosis. Good Response to Treatment Daratumumab attaches to the CD38 protein, found in large amounts on abnormal white blood cells in multiple myeloma and light chain amyloidosis. By attaching to CD38 on these cells, daratumumab activates the immune system to kill the abnormal white blood cells. Darzalex as monotherapy was investigated in two main studies involving multiple myeloma patients whose disease relapsed after, or was refractory to, at least two previous treatments, including a proteasome inhibitor and an immunomodulatory medicine. Response to treatment was measured by the disappearance of, or at least a 50% reduction in, protein produced by multiple myeloma cells. In the first study, around 29% of the patients who received daratumumab responded to treatment. In the second study, 36% of patients responded. In these studies, daratumumab was not compared with any other treatment. Full Indications The CHMP highlighted that the full indications for Darzalex solution for injection for will now be: For multiple myeloma: In combination with lenalidomide and dexamethasone or with bortezomib, melphalan, and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant In combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma In combination with bortezomib, thalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy For smoldering multiple myeloma: As monotherapy for the treatment of adult patients with smoldering multiple myeloma at high risk of developing multiple myeloma For light chain (AL) amyloidosis: In combination with cyclophosphamide, bortezomib, and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain amyloidosis The indications for Darzalex concentrate for solution for infusion remained unchanged, the CHMP said. Rob Hicks is a retired UK National Health Service doctor. A well-known TV and radio broadcaster, he has written several books and has regularly contributed to national newspapers, magazines, and online publications.
